

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number  
**WO 2004/041816 A1**

(51) International Patent Classification<sup>7</sup>: C07D 417/14,  
403/14, A61K 31/506, A61P 3/04

Park South, Third Avenue, Harlow, Essex CM19 5AW  
(GB).

(21) International Application Number:  
PCT/EP2003/012403

(74) Agent: LAWRENCE, Geoffrey, Mark, Prouse; Glaxo-SmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date:  
4 November 2003 (04.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
0225884.6 6 November 2002 (06.11.2002) GB

(71) Applicant (*for all designated States except US*): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

Published:

— with international search report


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and  
(75) Inventors/Applicants (*for US only*): BRANCH, Clive, Leslie [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PILLEUX, Jean-Pierre [FR/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PORTER, Roderick, Alan [GB/GB]; GlaxoSmithKline, New Frontiers Science

WO 2004/041816 A1

(54) Title: AZACYCLIC COMPOUNDS AS OREXIN RECEPTOR ANTAGONIST

(57) Abstract: This invention relates to compounds of formula (I) and their use as orexin antagonists.



## AZACYCLIC COMPOUNDS AS OREXIN RECEPTOR ANTAGONIST

This invention relates to tetrahydroquinoline and tetrahydroisoquinoline derivatives and their use as pharmaceuticals.

5 Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers.

10 Polypeptides and polynucleotides encoding the human 7-transmembrane G-protein coupled neuropeptide receptor, orexin-1 (HFGAN72), have been identified and are disclosed in EP-A-875565, EP-A-875566 and WO 96/34877. Polypeptides and polynucleotides encoding a second human orexin receptor, orexin-2 (HFGANP), have been identified and are disclosed in EP-A-893498.

15 Polypeptides and polynucleotides encoding polypeptides which are ligands for the orexin-1 receptor, e.g. orexin-A (Lig72A) are disclosed in EP-A-849361.

20 Orexin receptors are found in the mammalian host and may be responsible for many biological functions, including pathologies including, but not limited to, depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delerium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Gilles de la Tourett's syndrome; disturbed biological and circadian rhythms; feeding disorders, such as anorexia, bulimia, cachexia, and obesity; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome / disease; basophil adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; 25 hypophysis tumor / adenoma; hypothalamic diseases; Froehlich's syndrome; adrenohypophysis disease; hypophysis disease; hypophysis tumor / adenoma; pituitary growth hormone; adrenohypophysis hypofunction; adrenohypophysis hyperfunction; hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypopituitarism; hypothalamic hypothyroidism; hypothalamic- 30 adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; and sleep disturbances associated with such diseases as neurological disorders, neuropathic pain and restless leg syndrome, heart and lung diseases; acute and congestive heart failure; hypotension; hypertension; 35 urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischaemic or haemorrhagic stroke; subarachnoid haemorrhage; head injury such as sub-arachnoid haemorrhage associated with traumatic head injury; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain, such as hyperalgesia, 40 causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection, e.g. HIV, post-polio syndrome, and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-

operative pain; neuralgia; nausea and vomiting; conditions associated with visceral pain including irritable bowel syndrome, migraine and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders, which includes nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration, epilepsy, and seizure disorders.

Experiments have shown that central administration of the ligand orexin-A (described in more detail below) stimulated food intake in freely-feeding rats during a 4 hour time period. This increase was approximately four-fold over control rats receiving vehicle. These data suggest that orexin-A may be an endogenous regulator of appetite. Therefore, antagonists of its receptor may be useful in the treatment of obesity and diabetes, see *Cell*, 1998, **92**, 573-585.


There is a significant incidence of obesity in westernised societies. According to WHO definitions a mean of 35% of subjects in 39 studies were overweight and a further 22% clinically obese. It has been estimated that 5.7% of all healthcare costs in the USA are a consequence of obesity. About 85% of Type 2 diabetics are obese, and diet and exercise are of value in all diabetics. The incidence of diagnosed diabetes in westernised countries is typically 5% and there are estimated to be an equal number undiagnosed. The incidence of both diseases is rising, demonstrating the inadequacy of current treatments which may be either ineffective or have toxicity risks including cardiovascular effects. Treatment of diabetes with sulfonylureas or insulin can cause hypoglycaemia, whilst metformin causes GI side-effects. No drug treatment for Type 2 diabetes has been shown to reduce the long-term complications of the disease. Insulin sensitizers will be useful for many diabetics, however they do not have an anti-obesity effect.

Rat sleep/EEG studies have also shown that central administration of orexin-A, an agonist of the orexin receptors, causes a dose-related increase in arousal, largely at the expense of a reduction in paradoxical sleep and slow wave sleep 2, when administered at the onset of the normal sleep period. Therefore antagonists of its receptor may be useful in the treatment of sleep disorders including insomnia.

The present invention provides tetrahydroquinoline and tetrahydroisoquinoline derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors. In particular, these compounds are of potential use in the treatment of obesity, including obesity observed in Type 2 (non-insulin-dependent) diabetes patients, and/or sleep disorders. Additionally these compounds are useful in the treatment of stroke, particularly ischemic or haemorrhagic stroke, and/or blocking the emetic response, i.e. useful in the treatment of nausea and vomiting.

International Patent Applications WO99/09024, WO99/58533, WO00/47577 and WO00/47580 disclose phenyl urea derivatives and WO00/47576 discloses quinolinyl cinnamide derivatives as orexin receptor antagonists. WO01/96302 discloses N-aroyl cyclic amine derivatives.

According to the invention there is provided a compound of formula (I):



wherein:

- 5       $R^3$  and  $R^4$  together with the carbons to which they are attached form an aromatic or heteroaromatic ring and  $R^5$  and  $R^6$  are both H; or
- 10      $R^4$  and  $R^5$  together with the carbons to which they are attached form an aromatic or heteroaromatic ring and  $R^3$  and  $R^6$  are both H; or
- 15      $R^5$  and  $R^6$  together with the carbons to which they are attached form an aromatic or heteroaromatic ring and  $R^3$  and  $R^4$  are both H; and
- 20     m is 1 to 3;
- 25     p is 0 or 1;
- q is 0 or 1 provided that when q = 1, p = 0;
- X is NR, wherein R is H or  $(C_{1-4})$ alkyl;
- $Ar^1$  is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S, any of which may be optionally substituted;
- Ar<sup>2</sup> represents phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by  $R^1$  and further optional substituents,  $R^1$  representing hydrogen, optionally substituted  $(C_{1-4})$ alkoxy, halo, cyano, optionally substituted  $(C_{1-6})$ alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing up to 4 heteroatoms selected from N, O and S; or  $Ar^2$  represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 4 heteroatoms selected from N, O and S;
- 30     or a pharmaceutically acceptable salt thereof.

R is preferably H.

m is preferably 1.

p is preferably 0.

In a preferred embodiment m is 1 when p is 0 and q = 0.

In a further preferred embodiment when  $Ar^1$  is aryl p = 0.

In a still further preferred embodiment  $R^4$  and  $R^5$  together with the carbons to which they are attached form an aromatic ring thereby creating, together with the piperidine ring of formula (I), an isoquinolinyl bicyclic and wherein  $R^3$  and  $R^6$  are both H.

35     When  $Ar^1$  is an optionally substituted aryl it may have up to 5, preferably 1, 2 or 3 optional substituents.

Examples of when Ar<sup>1</sup> is a mono or bicyclic heteroaryl are quinoxaliny, quinazoliny, pyridopyraziny, benzoxazolyl, benzothiophenyl, benzimidazolyl, naphthyridiny, pyridinyl, pyrimidinyl, thiazolyl, pyridazinyl, pyrazinyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, quinolinyl, benzofuranyl, indolyl, benzothiazolyl, oxazolyl[4,5-

5 b]pyridiyl, pyridopyrimidinyl or isoquinolinyl, furanyl or thiienyl.

Preferably Ar<sup>1</sup> is pyrimidinyl.

When Ar<sup>2</sup> is a 5- or 6-membered heterocycl group containing up to 3 heteroatoms selected from N, O and S, it may be furanyl, thiienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl, 10 isothiazolyl, isoxazolyl, pyrazinyl or pyrazolyl.

When Ar<sup>2</sup> is an optionally substituted bicyclic aromatic or bicyclic heteroaromatic it is selected from benzofuryl, benzimidazolyl, quinolinyl, quinoxaliny, naphthyl, benzotriazolyl, benzothienyl, benzoxazolyl, naphthyridiny, isoquinolinyl, quinazoliny, indolyl, benzothiazolyl, or benzothiadiazolyl.

15 Preferably Ar<sup>2</sup> represents optionally substituted thiazolyl or pyrazolyl.

When R<sup>1</sup> is a 5- or 6-membered heterocycl group containing up to 4 heteroatoms selected from N, O and S, it may be phenyl, furanyl, thiienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazinyl, pyrimidinyl, 20 isothiazolyl, isoxazolyl, pyrazinyl, pyrazolyl, tetrazoyl, piperazinyl, piperidinyl, morpholinyl or thiomorpholinyl.

Preferably R<sup>1</sup> is optionally substituted phenyl.

Optional substituents for the groups Ar<sup>1</sup>, Ar<sup>2</sup>, and R<sup>1</sup> include halogen, hydroxy, oxo, cyano, nitro, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, hydroxy(C<sub>1-4</sub>)alkyl, hydroxy(C<sub>1-4</sub>)alkoxy, halo(C<sub>1-4</sub>)alkyl, halo(C<sub>1-4</sub>)alkoxy, aryl(C<sub>1-4</sub>)alkoxy, (C<sub>1-4</sub>)alkylthio, hydroxy(C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy(C<sub>1-4</sub>)alkyl, (C<sub>3-6</sub>)cycloalkyl(C<sub>1-4</sub>)alkoxy, (C<sub>1-4</sub>)alkanoyl, (C<sub>1-4</sub>)alkoxycarbonyl, (C<sub>1-4</sub>)alkylsulfonyl, (C<sub>1-4</sub>)alkylsulfonyloxy, (C<sub>1-4</sub>)alkylsulfonyl(C<sub>1-4</sub>)alkyl, arylsulfonyl,

25 arylsulfonyloxy, arylsulfonyl(C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkylsulfonamido, (C<sub>1-4</sub>)alkylamido, (C<sub>1-4</sub>)alkylsulfonamido(C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkylamido(C<sub>1-4</sub>)alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido(C<sub>1-4</sub>)alkyl, arylcarboxamido(C<sub>1-4</sub>)alkyl, aroyl, aroyl(C<sub>1-4</sub>)alkyl, or aryl(C<sub>1-4</sub>)alkanoyl group; a group R<sup>a</sup>R<sup>b</sup>N-, R<sup>a</sup>OCO(CH<sub>2</sub>)<sub>r</sub>, R<sup>a</sup>CON(R<sup>a</sup>)(CH<sub>2</sub>)<sub>r</sub>,

30 R<sup>a</sup>R<sup>b</sup>NCO(CH<sub>2</sub>)<sub>r</sub>, R<sup>a</sup>R<sup>b</sup>NSO<sub>2</sub>(CH<sub>2</sub>)<sub>r</sub> or R<sup>a</sup>SO<sub>2</sub>NR<sup>b</sup>(CH<sub>2</sub>)<sub>r</sub> where each of R<sup>a</sup> and R<sup>b</sup> independently represents a hydrogen atom or a (C<sub>1-4</sub>)alkyl group or where appropriate R<sup>a</sup>R<sup>b</sup> forms part of a (C<sub>3-6</sub>)azacycloalkane or (C<sub>3-6</sub>)(2-oxo)azacycloalkane ring and r represents zero or an integer from 1 to 4. Additional substituents are (C<sub>1-4</sub>)acyl, aryl, aryl(C<sub>1-4</sub>)alkyl,

35 (C<sub>1-4</sub>)alkylamino(C<sub>1-4</sub>)alkyl, R<sup>a</sup>R<sup>b</sup>N(CH<sub>2</sub>)<sub>n</sub>-, R<sup>a</sup>R<sup>b</sup>N(CH<sub>2</sub>)<sub>n</sub>O-, wherein n represents an integer from 1 to 4. Additionally when the substituent is R<sup>a</sup>R<sup>b</sup>N(CH<sub>2</sub>)<sub>n</sub>- or R<sup>a</sup>R<sup>b</sup>N(CH<sub>2</sub>)<sub>n</sub>O-, R<sup>a</sup> with at least one CH<sub>2</sub> of the (CH<sub>2</sub>)<sub>n</sub> portion of the group form a (C<sub>3-6</sub>)azacycloalkane and R<sup>b</sup> represents hydrogen, a (C<sub>1-4</sub>)alkyl group or with the nitrogen to which it is attached forms a second (C<sub>3-6</sub>)azacycloalkane fused to the first (C<sub>3-6</sub>)azacycloalkane.

40 Preferred optional substituents for Ar<sup>2</sup> are halogen and (C<sub>1-4</sub>)alkyl.

In a more preferred embodiment the optional substituent for Ar<sup>2</sup> is (C<sub>1-4</sub>)alkyl, most preferably (C<sub>1</sub>)alkyl (ie. methyl).

Preferred optional substituents for Ar<sup>1</sup> are halogen.

In a more preferred embodiment the optional substituent for Ar<sup>1</sup> is bromine.

5 Preferred optional substituents for R<sup>1</sup> are halogen.

In a more preferred embodiment the optional substituent for R<sup>1</sup> is fluorine.

In the groups Ar<sup>1</sup> and Ar<sup>2</sup>, substituents positioned *ortho* to one another may be linked to form a ring.

10 When a halogen atom is present in the compound of formula (I) it may be fluorine, chlorine, bromine or iodine.

When the compound of formula (I) contains an alkyl group, whether alone or forming part of a larger group, e.g. alkoxy or alkylthio, the alkyl group may be straight chain, branched or cyclic, or combinations thereof, it is preferably methyl or ethyl.

15 When used herein the term aryl means a 5- to 6- membered aromatic ring for example phenyl, or a 7 to 12 membered bicyclic ring system where at least one of the rings is aromatic for example naphthyl.

It will be appreciated that compounds of formula (I) may exist as *R* or *S* enantiomers. The present invention includes within its scope all such isomers, including mixtures. Where additional chiral centres are present in compounds of formula (I), the 20 present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

25 It will be understood that the invention includes pharmaceutically acceptable derivatives of compounds of formula (I) and that these are included within the scope of the invention.

Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable derivatives.

As used herein "pharmaceutically acceptable derivative" includes any 30 pharmaceutically acceptable salt, ester or salt of such ester of a compound of formula (I) which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will 35 be apparent to those skilled in the art and include acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Other salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of 40 this invention. Also included within the scope of the invention are solvates and hydrates of compounds of formula (I).

Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.

Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.


According to a further aspect of the present invention there is provided a process for the preparation of compounds of formula (I) and derivatives thereof. The following schemes detail some synthetic routes to compounds of the invention.

### Schemes

According to a further feature of the invention there is provided a process for the preparation of compounds of formula (I) and derivatives thereof. The following schemes detail some synthetic routes that may be used to prepare compounds of the invention.

Schemes 1a-c may be used to synthesise compounds wherein q = 0.  
 Scheme 2 may be used to synthesise compounds wherein q = 0 or 1.  
 Scheme 3 may be used to synthesise compounds wherein q = 1.

### Scheme 1a



wherein Ar<sup>1</sup>, Ar<sup>2</sup>, m, p and R, R<sup>3</sup> to R<sup>6</sup> are as defined for formula (I), q = 0, L<sup>1</sup> and L<sup>2</sup> are leaving groups, and P is a protecting group.


Examples of suitable leaving groups L<sup>1</sup> include halogen, hydroxy, OSO<sub>2</sub>Me, OSO<sub>2</sub>(4-tolyl). The reaction of (V) with (VI) preferably proceeds in an inert solvent such as N,N-dimethylformamide in the presence of a base such as triethylamine, sodium hydride or potassium t-butoxide.

Examples of suitable leaving groups L<sup>2</sup> include halogen, hydroxy, OC(=O)alkyl OC(=O)O-alkyl and OSO<sub>2</sub>Me. Acylation may be carried out using a wide range of known acylation conditions, e.g. in an inert solvent such as dichloromethane, in the presence of a base such as triethylamine. Alternatively these steps may be carried out when L<sup>2</sup> represents hydroxy, in which case the reaction takes place in an inert solvent such as dichloromethane in the presence of a diimide reagent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and an activator such as 1-hydroxybenzotriazole.

Examples of protecting group P include t-butyloxycarbonyl, trifluoroacetyl, optionally substituted benzyl and benzyloxycarbonyl. Deprotection conditions are respectively, acid (e.g. trifluoroacetic acid in dichloromethane), base (e.g. sodium hydroxide in a solvent such as aqueous methanol) and catalytic hydrogenolysis in an inert solvent (e.g. using palladium on charcoal in a lower alcohol or ethyl acetate).

20


### Scheme 1b



25

Reaction of (VIII) with (IX) proceeds in an inert solvent such as dimethylformamide or xylene in the presence of a base such as potassium carbonate or diisopropylethylamine, preferably at elevated temperatures. P can be a protecting group or H.

Alternatively where m is 1 and p is 0 or 1 compounds may be prepared as shown in scheme 1c.

**Scheme 1c**

5


Reaction of (XI) with an alkylating agent ( $C_{1-4}L^1$ ) proceeds in the presence of a base such as sodium hydride in an inert solvent such as dimethylformamide.

10 Compounds of formula (V), (VI), (IX), (X) are known in the literature or can be prepared by known methods. Compound (VIII) can be prepared by known methods.

Within the schemes above there is scope for functional group interconversion; for example in compound (V), conversion of one value of  $L^1$  to another value of  $L^1$ ; or in compounds (IV) conversion of protecting group P for another protecting group P, or 15 conversion of one compound of formula (I) to another of formula (I) by interconversion of substituents.

When  $R^1$  is an aromatic group, the substituent  $R^1$  may be introduced at the final stage as illustrated in Scheme 2 below by reaction of a compound of formula (VII) where  $L^3$  represents a leaving group such as halogen (preferably bromo or iodo) or trifluoromethylsulfonyloxy, and all other variables are as previously defined, with a reagent  $R^1M$ , where M is the residue of an organometallic species e.g.  $B(OH)_2$  or trialkylstannyl. Such a process may be carried out in an inert solvent such as 1,2-dimethoxyethane or 1,4-dioxan, in the presence of a transition metal catalyst such as  $Pd(PPh_3)_4$ .


20  
25**Scheme 2**



Wherein Ar<sup>2</sup>, Ar<sup>1</sup>, m, p, q, R, R<sup>1</sup> R<sup>3</sup> to R<sup>6</sup> are as defined for compounds of formula (I). L<sup>3</sup> is a leaving group.

5


### Scheme 3



10

wherein Ar<sup>1</sup>, Ar<sup>2</sup>, and R<sup>3</sup> to R<sup>6</sup> are as defined for formula (I), P is a protecting group, L<sup>2</sup> is a leaving group as defined above.

### 15 Scheme 4



wherein  $\text{Ar}^1$ ,  $\text{Ar}^2$ ,  $\text{R}^3$  to  $\text{R}^6$  are as defined for formula (I),  $\text{P}$  and  $\text{P}^1$  are protecting groups and  $\text{L}^2$  is a leaving group as defined above. Examples of protecting groups  $\text{P}$  and  $\text{P}^1$  are given in scheme 1a.

The starting materials for use in Schemes 1 to 4 are commercially available, well known in the literature or can be prepared by methods well known to the skilled person. Within the schemes above there is scope for functional group interconversion and for conversion of one value of  $\text{L}^1$  to another value of  $\text{L}^1$ ; or conversion of protecting group  $\text{P}$  or  $\text{P}^1$  to another protecting group  $\text{P}$  or  $\text{P}^1$ , or conversion of one compound of formula (I) to another of formula (I) by interconversion of substituents.

The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, e.g. 5 to 1000, preferably 10 to 100 compounds of formula (I). Compound libraries may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I), or pharmaceutically acceptable derivatives thereof.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are useful for the treatment of diseases or disorders where an antagonist of a human Orexin receptor is required such as obesity and diabetes; prolactinoma; hypoprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth hormone deficiency; Cushings syndrome/disease; hypothalamic-adrenal dysfunction; dwarfism; sleep

disorders; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases; depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety 5 neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; sexual disorder; schizophrenia; manic depression; delerium; dementia; bulimia and hypopituitarism. Additionally the compounds of formula (I) and pharmaceutically acceptable derivatives are useful for the treatment of stroke, particularly ischemic or haemorrhagic and/or in blocking an emetic response i.e. nausea and 10 vomiting.

The compounds of formula (I) and their pharmaceutically acceptable derivatives are particularly useful for the treatment of obesity, including obesity associated with Type 2 diabetes, and sleep disorders. Additionally the compounds of formula (I) and pharmaceutically acceptable derivatives are useful for the treatment of stroke, particularly 15 ischemic or haemorrhagic and/or in blocking an emetic response i.e. nausea and vomiting.

Other diseases or disorders which may be treated in accordance with the invention include disturbed biological and circadian rhythms; adrenohypophysis disease; hypophysis disease; hypophysis tumor / adenoma; adrenohypophysis hypofunction; functional or psychogenic amenorrhea; adrenohypophysis hyperfunction; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia and allodynia; 20 acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to infection e.g. HIV, post-polio syndrome and post-herpetic neuralgia; phantom limb pain; labour pain; cancer pain; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; and 25 tolerance to narcotics or withdrawal from narcotics.

The invention also provides a method of treating or preventing diseases or disorders where an antagonist of a human Orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.

The invention also provides a compound of formula (I), or a pharmaceutically acceptable derivative thereof, for use in the treatment or prophylaxis of diseases or disorders where an antagonist of a human Orexin receptor is required.

The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of a human Orexin receptor is required.

For use in therapy the compounds of the invention are usually administered as a pharmaceutical composition. The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

The compounds of formula (I) and their pharmaceutically acceptable derivatives may be administered by any convenient method, e.g. by oral, parenteral, buccal, sublingual,

nasal, rectal or transdermal administration, and the pharmaceutical compositions adapted accordingly.

The compounds of formula (I) and their pharmaceutically acceptable derivatives which are active when given orally can be formulated as liquids or solids, e.g. as syrups, suspensions, emulsions, tablets, capsules or lozenges.

A liquid formulation will generally consist of a suspension or solution of the active ingredient in a suitable liquid carrier(s) e.g. an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose and cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation procedures, e.g. pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), e.g. aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

Typical parenteral compositions consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active ingredient in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a disposable dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas e.g. air, or an organic propellant such as a fluorochlorohydrocarbon or hydrofluorocarbon. Aerosol dosage forms can also take the form of pump-atomisers.

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles where the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

Compositions suitable for transdermal administration include ointments, gels and patches.

Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.

The dose of the compound of formula (I), or a pharmaceutically acceptable derivative thereof, used in the treatment or prophylaxis of the abovementioned disorders or diseases will vary in the usual way with the particular disorder or disease being treated, the weight of the subject and other similar factors. However, as a general rule, suitable unit

doses may be 0.05 to 1000 mg, more suitably 0.05 to 500 mg. Unit doses may be administered more than once a day for example two or three times a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months. In the case of pharmaceutically acceptable derivatives the above figures are calculated as the parent compound of formula (I).

5 No toxicological effects are indicated/expected when a compound of formula (I) is administered in the above mentioned dosage range.

Human Orexin-A has the amino acid sequence:

pyroGlu Pro Leu Pro Asp Cys Cys Arg Gln Lys Thr Cys Ser Cys Arg Leu  
10 1 5 10 15  
Tyr Glu Leu Leu His Gly Ala Gly Asn His Ala Ala Gly Ile Leu Thr  
20 25 30  
Leu-NH<sub>2</sub>

Orexin-A can be employed in screening procedures for compounds which inhibit the 15 ligand's activation of the orexin-1 receptor.

In general, such screening procedures involve providing appropriate cells which express the orexin-1 receptor on their surface. Such cells include cells from mammals, yeast, Drosophila or *E. coli*. In particular, a polynucleotide encoding the orexin-1 receptor is used to transfet cells to express the receptor. The expressed receptor is then contacted 20 with a test compound and an orexin-1 receptor ligand to observe inhibition of a functional response. One such screening procedure involves the use of melanophores which are transfected to express the orexin-1 receptor, as described in WO 92/01810.

Another screening procedure involves introducing RNA encoding the orexin-1 receptor into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes are 25 then contacted with a receptor ligand and a test compound, followed by detection of inhibition of a signal in the case of screening for compounds which are thought to inhibit activation of the receptor by the ligand.

Another method involves screening for compounds which inhibit activation of the receptor by determining inhibition of binding of a labelled orexin-1 receptor ligand to cells 30 which have the receptor on their surface. This method involves transfeting a eukaryotic cell with DNA encoding the orexin-1 receptor such that the cell expresses the receptor on its surface and contacting the cell or cell membrane preparation with a compound in the presence of a labelled form of an orexin-1 receptor ligand. The ligand may contain a radioactive label. The amount of labelled ligand bound to the receptors is measured, e.g. by 35 measuring radioactivity.

Yet another screening technique involves the use of FLIPR equipment for high throughput screening of test compounds that inhibit mobilisation of intracellular calcium ions, or other ions, by affecting the interaction of an orexin-1 receptor ligand with the orexin-1 receptor.

40 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following Examples illustrate the preparation of pharmacologically active compounds of the invention. The Descriptions D1-D9 illustrate the preparation of intermediates to compounds of the invention. In the examples the following abbreviations are used: DMF is dimethylformamide, DCM is dichloromethane and THF is tetrahydrofuran.

**Description 1: 2-(4-Methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid**  
Sodium hydride (2.78g, 69mmol; 60% dispersion in oil) was added portionwise to a solution of isoquinoline-3-carboxylic acid (4.5g, 21mmol) in DMF (90ml) at room temperature under argon. After 1h, 4-methoxybenzyl chloride (6.9g, 44mmol) was added and the mixture stirred for 72h before being evaporated *in vacuo* and the residue partitioned between water and ethyl acetate. The organic phase was washed with brine, dried and concentrated *in vacuo* to give 4-methoxybenzyl 2-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylate (9.7g) as a yellow oil used without further purification.  
The crude ester was heated at 100°C in a mixture of dioxan (70ml) and 2M NaOH (70ml) for 16h and then cooled to room temperature. After a further 24h the reaction mixture was evaporated *in vacuo* and the residue partitioned between water and ethyl acetate. The aqueous phase was acidified with c.HCl and extracted with ethyl acetate. The combined extracts were dried and evaporated *in vacuo* to afford the title product (2.7g, 43%) as a yellow solid. <sup>1</sup>H NMR (DMSO) δ: 3.13 and 3.27 (2H, ABq, higher field arm, d, J = 16 and 4 Hz; lower field arm, d, J = 16 and 6Hz), 3.76 (3H, s), 3.95 – 4.16 (5H, m), 6.95 (2H, d, J = 8Hz), 7.10 – 7.20 (4H, m), 7.37 (2H, d, J = 8Hz), 11.0(1H, br s).

**Description 2: 2-(4-Methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid amide**  
To a solution of the acid from D1 (2.14g, 7.2mmol) in DCM (30ml) containing triethylamine (1.12ml, 8mmol) at 0°C under argon was added ethyl chloroformate (0.87g, 8mmol). After 20min, aqueous ammonia (16ml) was added in one portion and the resultant mixture vigorously stirred at room temperature for 20h. The aqueous layer was extracted with DCM and the combined DCM extracts dried, evaporated *in vacuo* to afford the title product (1.94g, 31%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 3.12 – 3.15 (2H, m), 3.54 – 3.68 (4H, m), 3.81 (3H, s), 3.83 – 3.86 (1H, m), 5.44 (1H, br s), 6.87 (2H, d, J = 7Hz), 7.00 (1H, m), 7.1 – 7.23 (6H, m).

**35 Description 3: C-(2-(4-Methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinolin-3-yl)-methylamine**

To the amide from D2 (1.94g, 6.54mmol) in dry THF (25ml) was added lithium aluminium hydride (13.1ml of a 1M soln in THF, 13.1mmol) and the mixture heated under argon at 70°C for 24h. The reaction mixture was cooled to room temperature and then water (2.6ml), 2M NaOH (2.9ml) and water (2.6ml) were carefully added sequentially. The suspension was filtered and the filtrate partitioned between ethyl acetate and brine, and the organic layer then dried and evaporated *in vacuo* to afford the title product (1.76g, 95%) as a

pale yellow solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 1.46 (2H, br s), 2.61 – 2.75 (2H, m), 2.89 – 2.96 (2H, m), 3.02 – 3.05 (1H, m), 3.6 – 3.67 (3H, m), 3.81 (3H, s), 3.78 – 3.83 (1H, m), 6.85 – 6.88 (2H, m), 6.95 – 6.96 (1H, m), 7.09 – 7.16 (3H, m), 7.25 – 7.26 (2H, m).

5 **Description 4: 2,2,2-Trifluoro-N-(2-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinolin-3-ylmethyl)-acetamide**

To a solution of the amine D3 (0.28g, 1mmol) in DCM (10ml) containing triethylamine (0.28ml, 2mmol) was added trifluoroacetic anhydride (0.252g, 1.2mmol) under argon at 0°C. The reaction mixture was allowed to reach room temperature and after stirring for 16h 10 was washed with brine, dried and evaporated *in vacuo*. The residue was chromatographed on silica gel to afford the title product (0.22g, 58%) as a yellow solid. Mass spectrum ( $\text{AP}^+$ ): Found 379 ( $\text{MH}^+$ ).  $\text{C}_{20}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_2$  requires 378.

15 **Description 5: 2,2,2-Trifluoro-N-(1,2,3,4-tetrahydro-isoquinolin-3-ylmethyl)-acetamide**

The product of D4 (1.32g, 3.5mmol) was dissolved in methanol (20ml) and formic acid (30ml) under argon at room temperature and 10%Pd/C (1.5g) added. After stirring for 20h 20 the reaction mixture was filtered through celite, washing thoroughly with methanol. The combined filtrate and washings were evaporated *in vacuo* to provide the title compound (1.47g, 100%) as a brown oil which was used without further purification. Mass spectrum ( $\text{AP}^+$ ): Found 259 ( $\text{MH}^+$ ).  $\text{C}_{12}\text{H}_{13}\text{F}_3\text{N}_2\text{O}$  requires 258.

25 **Description 6: 3-((2,2,2-Trifluoro-ethanoylamino)-methyl)-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid *tert*-butyl ester**

A mixture of the product from D5 (0.9g, 3.5mmol), triethylamine (1.7ml, 2mmol) and di-  
30 *tert*-butyl dicarbonate (1g, 4.5mmol) was stirred in DCM (40ml) for 20h at room temperature. The reaction mixture was washed with water and brine, and the aqueous phase back-extracted with DCM. The combined extracts were dried and evaporated *in vacuo* to afford the title compound (1.18g, 94%) as a brown solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 1.51 (9H, s), 2.70 – 2.75 (1H, m), 3.00 – 3.30 (4H, m), 4.32 – 4.68 (2H, m), 6.89 – 7.22 (4H, m), 7.90 (1H, br s).

35 **Description 7: 3-Aminomethyl-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid *tert*-butyl ester**

A mixture of the amide from D6 (1.18g, 3.2mmol), 1M potassium carbonate (15ml) and methanol (40ml) was stirred at room temperature for 56h. Methanol was evaporated *in vacuo* and the residue partitioned between water and chloroform. The aqueous phase was reextracted with chloroform and the combined extracts dried and evaporated to afford the title product (0.7g, 84%) as a brown oil.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 1.19 – 1.28 (2H, br s), 1.50 (9H, s), 2.55 – 2.60 (1H, m), 2.66 – 2.71 (1H, m), 2.75 – 2.79 (1H, m), 3.02 – 3.08 (1H, m), 4.22 – 4.26 (1H, m), 4.20 – 4.50 (1H, br s), 4.79 – 4.82 (1H, m), 7.10 – 7.20 (4H, m).

40 **Description 8: 3-((5-Bromo-pyrimidin-2-ylamino)-methyl)-3,4-dihydro-1*H*-isoquinoline-2-carboxylic acid *tert*-butyl ester**

A mixture of the amine from D7 (0.7g, 2.7mmol), 5-bromo-2-chloropyrimidine (0.62g, 3.2mmol), diisopropylethylamine (1.9ml, 2.7mmol) and potassium carbonate (0.83g, 6mmol) in xylene (12ml) was refluxed for 20h, cooled, filtered and the filtrate evaporated *in vacuo*. The residue was chromatographed on silica gel and the product containing fractions 5 combined, evaporated and the residue triturated with ether to afford the title product (0.45g, 40%) as a pale yellow solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 1.45 (9H, s), 2.73 – 2.77 (1H, m), 3.09 – 3.15 (1H, m), 3.27 – 3.34 (1H, m), 3.39 (1H, br s), 4.25 – 4.30 (1H, m), 4.75 (2H, br s), 5.30 (0.5H, br s), 5.60 (0.5H, br s), 7.11 – 7.20 (4H, m), 8.23 (2H, m).

10 **Description 9: (5-Bromo-pyrimidin-2-yl)-(1,2,3,4-tetrahydro-isoquinolin-3-ylmethyl)-amine**

A solution of the product from D8 (0.43g, 1mmol) in DCM (20ml) containing trifluoroacetic acid (4ml) was stirred at room temperature for 20h, evaporated *in vacuo* and the residue partitioned between chloroform and 1M sodium hydroxide. The aqueous phase 15 was extracted with chloroform and the combined extracts dried and evaporated *in vacuo* to afford the title product (0.31g, 97%) as a white solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 1.97 (1H, br s), 2.61 – 2.68 (1H, m), 2.83 – 2.88 (1H, m), 3.22 – 3.25 (1H, m), 3.33 – 3.40 (1H, m), 3.66 – 3.72 (1H, m), 4.08 (2H, s), 5.81 (1H, br s), 7.02 – 7.04 (1H, m), 7.04 – 7.15 (3H, m), 8.28 (2H, s).

20 **Example 1: 1-(3-((5-Bromo-pyrimidin-2-ylamino)-methyl)-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl)-methanone**  
To the amine of D9 (0.155g, 0.5mmol) in dimethylformamide (8ml) containing diisopropylethylamine (0.26ml, 1.5mmol) was added [O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (0.247g, 0.65mmol) followed by 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid (0.143g, 0.6mmol). After 10 days at room 25 temperature the reaction mixture was evaporated and the residue partitioned between ethyl acetate and saturated aqueous  $\text{NaHCO}_3$ . The aqueous phase was back extracted and the combined extracts dried and evaporated. Trituration with acetone afforded the title product (0.128g, 48%). Mass spectrum ( $\text{AP}^+$ ): Found 538 ( $\text{MH}^+$ ).  $\text{C}_{25}\text{H}_{21}{^{79}\text{BrF}}\text{N}_5\text{OS}$  requires 537.

30 **Example 2: 1-(3-((5-Bromo-pyrimidin-2-ylamino)-methyl)-3,4-dihydro-1*H*-isoquinolin-2-yl)-1-(4-(4-fluoro-phenyl)-1-methyl-1*H*-pyrazol-3-yl)-methanone**

The title compound was obtained from the amine of D9 (0.155g, 0.5mmol) and 4-(4-fluoro-phenyl)-1-methyl-1*H*-pyrazole-3-carboxylic acid (0.132g, 0.6mmol) using the method of 35 Example 1, except that the product was isolated by chromatography on silica gel eluting with an ethyl acetate/pentane gradient. Mass spectrum ( $\text{AP}^+$ ): Found 521 ( $\text{MH}^+$ ).  $\text{C}_{25}\text{H}_{22}{^{79}\text{BrF}}\text{N}_6\text{O}$  requires 520.

40 It is understood that the present invention covers all combinations of particular and preferred groups described herein above.

**Determination of Orexin-1 Receptor Antagonist Activity**

The orexin-1 receptor antagonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

5    **Experimental Method**

CHO-DG44 cells expressing the human orexin-1 receptor were grown in cell medium (MEM medium with Earl's salts) containing 2 mM L-Glutamine, 0.4 mg/mL G418 Sulphate from GIBCO BRL and 10% heat inactivated fetal calf serum from Gibco BRL. The cells were seeded at 20,000 cells/100 µl/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10 µg/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37C in 5% CO<sub>2</sub>.

Agonists were prepared as 1 mM stocks in water:DMSO (1:1). EC50 values (the concentration required to produce 50% maximal response) were estimated using 11x half log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, 10mM glucose, 2.5 mM KCl, 1.5 mM CaCl<sub>2</sub>, 1.2 mM MgCl<sub>2</sub> and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%). Antagonist IC50 values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 3.0 nM human orexin-A using 11x half log unit dilutions in Tyrode's buffer containing 10% DMSO and probenecid.

On the day of assay 50 µl of cell medium containing probenecid (Sigma) and Fluo3AM (Texas Fluorescence Laboratories) was added (Quadra, Tomtec) to each well to give final concentrations of 2.5 mM and 4 µM, respectively. The 96-well plates were incubated for 60 min at 37C in 5% CO<sub>2</sub>. The loading solution containing dye was then aspirated and cells were washed with 4x150 µl Tyrode's buffer containing probenecid and 0.1% gelatin (Denley Cell Wash). The volume of buffer left in each well was 125 µl. Antagonist or buffer (25 µl) was added (Quadra) the cell plates gently shaken and incubated at 37C in 5% CO<sub>2</sub> for 30 minutes. Cell plates were then transferred to the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) instrument. Prior to drug addition a single image of the cell plate was taken (signal test), to evaluate dye loading consistency. The run protocol used 60 images taken at 1 second intervals followed by a further 24 images at 5 second intervals. Agonists were added (by the FLIPR) after 20 seconds (during continuous reading). From each well, peak fluorescence was determined over the whole assay period and the mean of readings 1-19 inclusive was subtracted from this figure. The peak increase in fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter logistic fit (as described by Bowen and Jerman, *TiPS*, 1995, **16**, 413-417) to generate a concentration effect value. Antagonist Kb values were calculated using the equation:

$$Kb = IC50 / (1 + ([3] / EC50))$$

where EC50 was the potency of human orexin-A determined in the assay (in nM terms) and IC50 is expressed in molar terms.

Compounds of Examples tested according to this method had pKb values of greater than 6.8 at the human cloned orexin-1 receptor.

## Determination of Orexin-2 Receptor Antagonist Activity

The orexin-2 receptor antagonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

5

### Experimental Method

CHO-DG44 cells expressing the human orexin-2 receptor were grown in cell medium (MEM medium with Earl's salts) containing 2 mM L-Glutamine, 0.4 mg/mL G418 Sulphate from GIBCO BRL and 10% heat inactivated fetal calf serum from Gibco BRL.

10 The cells were seeded at 20,000 cells/100 µl/well into 96-well black clear bottom sterile plates from Costar which had been pre-coated with 10 µg/well of poly-L-lysine from SIGMA. The seeded plates were incubated overnight at 37C in 5% CO<sub>2</sub>.

15 Agonists were prepared as 1 mM stocks in water:DMSO (1:1). EC50 values (the concentration required to produce 50% maximal response) were estimated using 11x half log unit dilutions (Biomek 2000, Beckman) in Tyrode's buffer containing probenecid (10 mM HEPES with 145mM NaCl, 10mM glucose, 2.5 mM KCl, 1.5 mM CaCl<sub>2</sub>, 1.2 mM MgCl<sub>2</sub> and 2.5mM probenecid; pH7.4). Antagonists were prepared as 10 mM stocks in DMSO (100%). Antagonist IC50 values (the concentration of compound needed to inhibit 50% of the agonist response) were determined against 10.0 nM human orexin-A using 11x half log unit dilutions in Tyrode's buffer containing 10% DMSO and probenecid.

20 On the day of assay 50 µl of cell medium containing probenecid (Sigma) and Fluo3AM (Texas Fluorescence Laboratories) was added (Quadra, Tomtec) to each well to give final concentrations of 2.5 mM and 4 µM, respectively. The 96-well plates were incubated for 60 min at 37C in 5% CO<sub>2</sub>. The loading solution containing dye was then 25 aspirated and cells were washed with 4x150 µl Tyrode's buffer containing probenecid and 0.1% gelatin (Denley Cell Wash). The volume of buffer left in each well was 125 µl. Antagonist or buffer (25 µl) was added (Quadra) the cell plates gently shaken and incubated at 37C in 5% CO<sub>2</sub> for 30 min. Cell plates were then transferred to the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) instrument. Prior to drug addition a single image 30 of the cell plate was taken (signal test), to evaluate dye loading consistency. The run protocol used 60 images taken at 1 second intervals followed by a further 24 images at 5 second intervals. Agonists were added (by the FLIPR) after 20 sec (during continuous reading). From each well, peak fluorescence was determined over the whole assay period and the mean of readings 1-19 inclusive was subtracted from this figure. The peak increase 35 in fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter logistic fit (as described by Bowen and Jerman, *TiPS*, 1995, 16, 413-417) to generate a concentration effect value. Antagonist Kb values were calculated using the equation:

$$K_b = IC50 / (1 + ([3] / EC50))$$


40 where EC50 was the potency of human orexin-A determined in the assay (in nM terms) and IC50 is expressed in molar terms.

Compounds of Examples tested according to this method had pK<sub>b</sub> values of less than 7.0 at the human cloned orexin-2 receptor.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take  
5 the form of product, composition, process, or use claims and may include, by way of example and without limitation the following claims:

## CLAIMS

1. A compound of formula (I):



5

(I)

wherein:

R<sup>3</sup> and R<sup>4</sup> together with the carbons to which they are attached form an aromatic or heteroaromatic ring and R<sup>5</sup> and R<sup>6</sup> are H; or

10 R<sup>4</sup> and R<sup>5</sup> together with the carbons to which they are attached form an aromatic or heteroaromatic ring and R<sup>3</sup> and R<sup>6</sup> are H; or

R<sup>5</sup> and R<sup>6</sup> together with the carbons to which they are attached form an aromatic or heteroaromatic ring and R<sup>3</sup> and R<sup>4</sup> are H; and

m is 1 to 3;

15 p is 0 or 1;

q is 0 or 1 provided that when q = 1, p = 0;

X is NR, wherein R is H or (C<sub>1-4</sub>)alkyl;

Ar<sup>1</sup> is aryl, or a mono or bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S, any of which may be optionally substituted;

20 Ar<sup>2</sup> represents phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by R<sup>1</sup> and further optional substituents, R<sup>1</sup> representing hydrogen, optionally substituted

(C<sub>1-4</sub>) alkoxy, halo, cyano, optionally substituted (C<sub>1-6</sub>)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing up to 4 heteroatoms selected from N, O and S; or

25 Ar<sup>2</sup> represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 4 heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt thereof.

30

2. A compound according to claim 1 wherein R is H.

3. A compound according to claim 1 or 2 wherein m is 1.

- 35 4. A compound according to any one of claims 1 to 3 wherein p is 0.

5. A compound according to any one of claims 1 to 4 wherein m is 1 when p is 0 and q = 0.

6. A compound according to any one of claims 1 to 5 wherein R<sup>4</sup> and R<sup>5</sup> together with  
5 the carbons to which they are attached form an aromatic ring thereby creating, together with  
the piperidine ring of formula (I), an isoquinolinyl bicyclic and wherein R<sup>3</sup> and R<sup>6</sup> are both  
H.

7. A compound according to any one of claims 1 to 6 wherein Ar<sup>1</sup> is pyrimidinyl.  
10

8. A compound according to any one of claims 1 to 7 wherein Ar<sup>2</sup> is thiazolyl or  
pyrazolyl.

9. A compound according to any one of claims 1 to 8 wherein R<sup>1</sup> is phenyl.

15 10. A pharmaceutical composition comprising a compound of formula (I) as defined in  
any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and a  
pharmaceutically acceptable carrier.

20 11. Use of a compound of formula (I) as defined in any one of claims 1 to 9 in the  
manufacture of a medicament for the treatment of disorders where an antagonist of a human  
orexin receptor is required.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/12403

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/14 C07D403/14 A61K31/506 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, CHEM ABS Data, WPI Data, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 985 881 A (MEHRHOF WERNER ET AL) 12 October 1976 (1976-10-12) column 11, line 31; claim 1; example 1 column 11, line 35 ----- PATENT ABSTRACTS OF JAPAN vol. 1997, no. 08, 29 August 1997 (1997-08-29) & JP 9 104674 A (KOTOBUKI SEIYAKU KK), 22 April 1997 (1997-04-22) see Formula (I) abstract ----- -/-	1-10
X		1-10

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 "&" document member of the same patent family

Date of the actual completion of the international search  16 February 2004	Date of mailing of the international search report  02/03/2004
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Usuelli, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/12403

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;</p> <p>NAGATA, MASANORI: "Synthesis in azabenzoc!quinolizine group. IV. Synthesis of 2,3,4,4a,5,6-hexahydro-1H-pyridazo[2,3-a]quinoline derivatives"</p> <p>XP002270484 retrieved from STN Database accession no. 1966:482206 see RN 7521-58-6 abstract &amp; YAKUGAKU ZASSHI , 86(7), 608-13 CODEN: YKKZAJ; ISSN: 0031-6903, 1966,</p> <p>-----</p>	1-9
A	WO 01/096302 A (BRANCH CLIVE LESLIE ; JOHNSON CHRISTOPHER NORBERT (GB); THEWLIS KEVIN) 20 December 2001 (2001-12-20) page 2, line 25 - page 3, line 10; claim 1	1-11
A	WO 01/068609 A (FISCHLI WALTER ; ACTELION PHARMACEUTICALS LTD (CH); CAPPI MICHAEL (DE)) 20 September 2001 (2001-09-20) page 2, line 22 - page 4, line 6; claim 1	1-11
P,A	EP 1 288 202 A (BANYU PHARMA CO LTD) 5 March 2003 (2003-03-05) paragraph '0011! - paragraph '0013!; claim 1	1-11
	-----	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/12403

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 3985881	A	12-10-1976	DE AT AT AT AU BE CA CH CS CS DD DK ES FR GB HU JP NL PL SE ZA	2361390 A1 748077 A 351026 B 981974 A 7625774 A 823027 A1 1053675 A1 605776 A5 188949 B2 188933 B2 115666 A5 639674 A , B, 432716 A1 2253522 A1 1447611 A 171483 B 50088077 A 7416050 A 93405 B1 7415247 A 7407820 A		19-06-1975 15-09-1979 10-07-1979 15-12-1978 10-06-1976 06-06-1975 01-05-1979 13-10-1978 30-03-1979 30-03-1979 12-10-1975 11-08-1975 01-03-1977 04-07-1975 25-08-1976 28-01-1978 15-07-1975 12-06-1975 30-05-1977 11-06-1975 31-12-1975
JP 9104674	A	22-04-1997		NONE		
WO 0196302	A	20-12-2001	AU WO EP US	7247601 A 0196302 A1 1289955 A1 2003186964 A1		24-12-2001 20-12-2001 12-03-2003 02-10-2003
WO 0168609	A	20-09-2001	AU BR CA CN WO EP HU JP NO	6011301 A 0109200 A 2402431 A1 1416420 T 0168609 A1 1274687 A1 0300207 A2 2003527374 T 20024339 A		24-09-2001 03-06-2003 20-09-2001 07-05-2003 20-09-2001 15-01-2003 28-05-2003 16-09-2003 11-09-2002
EP 1288202	A	05-03-2003	AU CA EP WO	5265701 A 2408343 A1 1288202 A1 0185693 A1		20-11-2001 07-11-2002 05-03-2003 15-11-2001